Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. It blocks viral entry into host cells while preserving normal immunologic function. The Company is also investigating an intramuscular method of administration of Trogarzo. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy.

TSX:TH - Post by User

Theratechnologies Inc > Novel precision technology

<< Previous

Bullboard Posts

Next >>

Comment by Biobobon Oct 27, 2022 2:45pm

78 Views

Post# 35053956

RE:RE:RE:RE:RE:Novel precision technology

I understand your point but these companies have the resources to evaluate the risk (like Solueus) and basically logic would make Thera a stupid buy for even the risk averse Pharma considering the legacy sales, th FX discount, the near death experience of the biotech sector and of course the potential. But I'm told on a regular basis that Pharma don't think like that. Paul use to be the one in that position at Pfizer, shurely it must at least intreague some former collegues or competitors.

<< Previous

Bullboard Posts

Next >>

A junior copper-gold stock trading at a bargain of monumental proportions